Prof Toh Han Chong Co-Founder and Chief Medical Officer NeoTila Biosciences Inc. He is also Deputy CEO (Strategic Partnerships), National Cancer Centre Singapore and Professor at Duke NUS Medical School. He completed the International Baccalaureate at Lester B Pearson College, British Columbia, Canada, on a United World College scholarship, obtained his BSc (Intercalated) from the University of London in ‘Infection and Immunity’ and his medical degree from the University of Cambridge, UK. His oncology and research fellowships were at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas, USA. Dr Toh is alumni of the Harvard Business School General Management Program. He received the National Senior Clinician Scientist Award in 2017, National Medical Excellence Award (NMEA) in 2018 and the Singapore Translational Research Investigator Award (STaR) in 2022. Dr Toh is a co-founder of the Asia-Pacific Gastrointestinal Cancer Summit (APGCS). He serves on the Scientific Faculty of the European Society for Medical Oncology (ESMO) for Investigational Immunotherapy and is Chair of the Investigational Immunotherapy.
